[7] IMS Health's products and services were used by companies to develop commercialization plans[8] and portfolio strategies,[9] to select patient and physician populations for specific therapies, and to measure the effectiveness of pharmaceutical marketing and sales resources.

[2] Throughout its history, the legacy IMS Health's business of collecting anonymized pharmaceutical sales data came under scrutiny from both the media and the legal system.

[32][33][34][35] IQVIA was contracted by the UK government's Office of National Statistics to provide data on the prevalence of COVID-19 infection in the population.

[36] The problems with how the survey results were collected were criticised for potentially leading to biased data by New Scientist.

[37] On July 17, 2023, the Federal Trade Commission sued to block IQVIA’s acquisition of Propel Media alleging in an administrative complaint that the acquisition would give IQVIA a market-leading position in health care programmatic advertising and would raise health-care prices for consumers.

In December 2023, U.S. District Court Judge Edgardo Ramos issued an order granting the FTC’s motion for preliminary injunction to block the merger.

Despite the ongoing war, the company has maintained its presence and activities in Russia, providing services in the pharmaceutical and biopharmaceutical sectors.